MCL1 and melanoma: The antitumor potency of Mcl-1 antisense oligonucleotides either alone or in combination with other conventional therapeutics has been demonstrated in a wide variety of human cancers including chronic myeloid leukemia (CML) [94], sarcoma [103], hepatocellular carcinoma [13], gastric cancer [104] and melanoma [105].